Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Earnings Press Release furnished as Exhibit 99.1, containing the substantive financial details
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue $35.3M, down 7.8% YoY, as oncology declines outweighed Acute Care growth
- ZYNRELEF revenue $10.6M, up 13.8%; APONVIE revenue $4.5M, up 49.3%
- CINVANTI revenue $20.0M, down 16.6%; SUSTOL sales ceased September 30, 2026
- Net loss narrowed to $5.0M from $17.5M; adjusted EBITDA improved to $3.7M from $1.5M
- Proposed CorMedix asset sale, subject to stockholder approval, makes transaction completion the key near-term catalyst and risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.